Ablynx NV, a Belgian company that produces a novel class of therapeutic proteins based on single domain antibody fragments, has appointed Josefin-Beate Holz to the newly created position of chief medical officer.
She will head up the preclinical and clinical activities of Ablynx.
Prior to joining Ablynx, Dr Holz was head of preclinical and clinical development, manufacturing and regulatory affairs at U3 Pharma AG.
Source:
Ablynx press release, 6 August 2007
Copyright 2007 Evernow Publishing Ltd